8-(Heteroaryl)phenalkyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-ones as opioid receptor modulators.

Med Chem

Drug Discovery Division, Johnson & Johnson Pharmaceutical Research and Development, LLC, P.O. Box 776, Welsh and McKean Rds., Spring House, PA 19477-0777, USA.

Published: November 2005

AI Article Synopsis

Article Abstract

A series of N-biarylalkyl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-ones were prepared and evaluated for biological activity at opioid (mu, delta, kappa) and opioid receptor like-1 (ORL-1) G-protein coupled receptors. Substitution on the biaryl moiety produced enhanced affinity for the mu-opioid receptor.

Download full-text PDF

Source
http://dx.doi.org/10.2174/157340605774598207DOI Listing

Publication Analysis

Top Keywords

opioid receptor
8
8-heteroarylphenalkyl-1-phenyl-138-triazaspiro[45]decan-4-ones opioid
4
receptor modulators
4
modulators series
4
series n-biarylalkyl-1-phenyl-138-triazaspiro[45]decan-4-ones
4
n-biarylalkyl-1-phenyl-138-triazaspiro[45]decan-4-ones prepared
4
prepared evaluated
4
evaluated biological
4
biological activity
4
activity opioid
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!